MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Matthew Fell(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. Morrow(Merck & Co., Inc., Rahway, NJ, USA (United States)), Duane E. DeMong(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eric M. Parker(University of New Hampshire), Michael A. Miller(University of Alabama at Birmingham), Matthew Kennedy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christian Mirescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhizhang Yin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jack D. Scott(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kallol Basu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaoping Zhou, Yinghui Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hong Mei(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carrie G. Markgraf(Merck & Co., Inc., Rahway, NJ, USA (United States)), J. Michael Ellis(Bristol-Myers Squibb (United States)), Lynn A. Hyde(Merck & Co., Inc., Rahway, NJ, USA (United States)), Boonlert Cheewatrakoolpong(Merck & Co., Inc., Rahway, NJ, USA (United States)), Frederique M. Poulet, Michelle Smith(Merck & Co., Inc., Rahway, NJ, USA (United States))
Journal of Pharmacology and Experimental Therapeutics
September 26, 2015
Cited by 336


Related Papers